NewCardio, Inc. (OTCBB: NWCI), a cardiac diagnostic and services company, today announced that Peter R. Kowey MD., an industry-leading cardiologist who has served on numerous prestigious committees and is a Fellow of several professional organizations, has agreed to join the Company’s scientific advisory board.

Dr. Kowey is currently President of the Heart Center of the Lankenau Hospital Main Line Health System. He also is Professor of Medicine and Clinical Pharmacology at Jefferson Medical College and previously served as an adjunct professor of pharmacology at MCP-Hahnemann School of Medicine. Dr. Kowey’s principal area of interest has been cardiac rhythm disturbances. He has been the recipient of over 150 grants and has authored or co-authored more than 400 papers and scientific reports. Dr. Kowey is a Fellow of several professional organizations including the Clinical Council of the American Heart Association, the American College of Cardiology, the American College of Physicians, the College of Physicians of Philadelphia, the American College of Chest Physicians, and the American College of Clinical Pharmacology. He spent nine years as a member of the Cardiorenal Drug Advisory Committee, four years on the Cardiovascular Devices Committee of the U.S. Food and Drug Administration, and is on the Expert Advisory Panel of the U.S. Pharmacopeial convention. In addition, he serves as an ad-hoc consultant to 94 organizations, including many of the largest pharmaceutical companies in the world, such as Pfizer, Merck, GlaxoSmithKline, Amgen, Eli Lilly and Company, and Bristol-Myers Squibb. He has also chaired several data and safety monitoring boards for clinical trials. His experience with clinical studies and his relationship with more than 60 leading pharmaceutical companies will be of particular interest to NewCardio as the Company continues the commercialization of its lead product, the Qtinno , which is intended to bring full automation to the process of testing new drugs for cardiac toxicity.

Dr. Kowey was a founding member of the Philadelphia Arrhythmia Group and a charter member of the North American Society of Pacing and Electrophysiology. He is the co-editor of three textbooks regarding cardiac arrhythmia and serves as a referee for manuscript review for 25 journals, as well as sitting on the editorial boards of the Heart Rhythm Journal and the Journal of Cardiovascular Electrophysiology. Dr. Kowey graduated from St Joseph’s University and the University Of Pennsylvania School Of Medicine in Philadelphia. He completed his residency training in internal medicine at Pennsylvania State University and was a Fellow in cardiovascular medicine and research at the Harvard University School of Public Health, the Peter Bent Brigham Hospital, and the West Roxbury VA Hospital.

Branislav Vajdic, Ph.D., President and Chief Executive Officer, commented, “Dr. Kowey is a well-respected physician and a leader in the area of cardiac rhythm disturbances, and his expertise and reputation should significantly augment our scientific advisory board. He has pioneered the development of many antiarrhythmic drugs and antitachycardia devices that are used around the world for the treatment of patients with life-threatening cardiac rhythm problems. In addition, his work with more than 60 leading pharmaceutical organizations and his significant background in the completion of clinical trials should bring tremendous value to NewCardio. As we commercialize our Qtinno product and bring modern computer processing to thorough QT testing, we expect that Dr. Kowey’s longstanding relationships with some of the largest pharmaceutical companies in the world and his excellent industry reputation should accelerate our commercialization process and that his expertise should help our product meet the needs of the industry. We welcome Dr. Kowey to NewCardio and look forward to benefiting from his expertise as we develop our 3D platform technology.”

Dr. Kowey added, “I am excited to work with NewCardio and look forward to advancing this innovative and important technology. I believe this platform offers the opportunity to enhance the diagnostic value of the electrocardiograph, streamline cardiac toxicity testing in pharmaceutical clinical trials and potentially improve clinical outcomes in patients with cardiovascular disease.”

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio’s development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio’s three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.